PRIMARY OBJECTIVE:~I. To determine if treatment with lopinavir/ritonavir will decrease progression of symptoms compared to control/placebo.~SECONDARY OBJECTIVES:~I. Determine if treatment improves time to symptom resolution. II. Determine the time to symptom progression. III. Determine time to improvement of participants as defined by complete resolution of symptoms.~IV. Determine the proportion of participants who have severe or critical symptoms and hospital admission.~V. Determine the time to hospital admission for those who develop severe of critical symptoms VI. Determine the proportion of participants with an intensive care unit (ICU) admission.~VII. Determine the proportion of participants receiving ventilator support. VIII. Determine survival of participants enrolled on the study.~EXPLORATORY OBJECTIVES:~I. For patients admitted to the hospital, will determine the following parameters: potassium level, blood oxygen level, creatinine, and blood pressure.~II. Identify obstacles and barriers encountered while implementing a clinical trial in the context of a pandemic caused by a contagious disease and associated social distancing.~OUTLINE: Patients are randomized to 1 of 2 groups.~GROUP I: Patients receive lopinavir/ritonavir orally (PO) twice daily (BID) for 14 days in the absence of disease progression or unacceptable toxicity.~GROUP II: Patients receive placebo PO BID for 14 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up 3 times a week until symptoms resolve plus 2 additional weeks thereafter, for up to 3 months, whichever occurs first.
This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.